LP-0145 is under clinical development by Leo Pharma and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LP-0145’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LP-0145 (ARGX-112) is under development for the treatment of atopic dermatitis. The drug candidate is a fully human monoclonal antibody which targets IL22R. The drug candidate is developed based on SIMPLE antibody platform and NHance technologies. It is administered through subcutaneous route.
Leo Pharma overview
Leo Pharma, a subsidiary of LEO Foundation, is a drug manufacturing company. It discovers, develops, manufactures, and commercializes medicines for skin diseases and thrombosis. Its product portfolio spans pharmaceuticals for the treatment of diseases such as eczema, psoriasis, skin infections, actinic keratosis, non-melanoma skin cancer and thrombosis. The company also manufactures and markets products for the treatment of bacterial infections, coagulation, cardiovascular, antibiotics, nutritional disorders, osteoporosis, and renal problems. Leo Pharma markets its products worldwide. The company has a presence in Europe, the Middle East, Africa, Asia, the Americas, and Oceania. Leo Pharma is headquartered in Ballerup, Denmark.
For a complete picture of LP-0145’s drug-specific PTSR and LoA scores, buy the report here.